Cooperative Agreement U01NS074480

This $459,613 Project Grant awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program aims to investigate modulating endogenous opioid signaling as a potential treatment for deficits in reward processing associated with psychiatric disorders. The project will administer a drug that inhibits the degradation of endogenous enkephalins to chronically stressed mice and record neural activity in reward-related brain regions as the mice...

Cooperative Agreement Summary ATAI Therapeutics, Inc. received a $2.92 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective August 15, 2025 through June 30, 2027. The award funds the optimization and development of non-hallucinogenic 5-HT2A/2C receptor agonists as therapeutic candidates for opioid use disorder (OUD). ATAI will advance two lead chemical series (EGX-J and EGX-I) that leverage...

The National Institute of Mental Health (NIMH) awarded a $156,500 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to Emory University to identify patients with true treatment failure for major depressive disorder (MDD) who may benefit from earlier referral to alternative treatments like transcranial magnetic stimulation, ketamine, and vagus nerve stimulation. The project aims to use trajectory classification methods to empirically separate partial response from true...

This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...

This $576,337 National Institute of Mental Health project grant funds research at Stanford University to evaluate a biomarker-guided intervention approach for anhedonia in treatment-resistant depression. The grant supports a clinical trial targeting D3 receptor agonism with pramipexole to determine its effects on ventral striatum brain activation as measured by functional neuroimaging. The study aims to enroll treatment-resistant depression patients with prominent anhedonia to evaluate whether...

This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...

Federal Grant Award Summary Jillion Therapeutics Inc. received a $399,483 Phase I Small Business Innovation Research (SBIR) Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) effective May 15, 2025 through April 30, 2027. The company is developing novel polypharmacological therapeutic compounds to treat substance use disorders by combining artificial intelligence (AI) with its proprietary DNA-encoded library (DEL) drug...

Federal Grant Award Summary Dark Matter Therapeutics, Inc. received a $798,828 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop novel therapeutics for opioid use disorder (OUD). The award, issued on May 1, 2025, with completion targeted for April 30, 2027, supports the development and application of an artificial intelligence platform designated M3.AI (Multi-cell type, Multi-objective, Multi-target AI) for...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $387,000.00 to Florida Atlantic University to develop novel intranasal delivery cyclic peptide analgesics for pain management. The research aims to create new peptide-based pain medications that combine kappa-opioid receptor agonist activity with serotonin and/or norepinephrine delivery, with the goal of improving pain relief while minimizing...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...